ERBB2 and triple-negative breast carcinoma: A total of 363 breast cancer patients were included in this study, and 254 breast cancer patients were finally included, including 148 cases of HR+/HER2− breast cancer, 57 cases of HER2+ breast cancer, and 49 cases of Triple-Negative Breast Cancer (TNBC).